NRP1 and neoplasm: In the AVAGAST trial, it has been shown that the assessment of circulating VEGF-A and tumor levels of NRP1 could aid the selection of patients with advanced or metastatic gastric cancer who are more likely to benefit from the addition of bevacizumab to the chemotherapeutic protocol.